Jobs
-
Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad… Read more . . .
-
H&T Presspart has acquired Swiss device maker Novelex (formerly Forteq Nidau), the company said, and all Novelex employees will be absorbed into H&T Presspart. The company acquired Novelex from Liberta Partners, which had acquired Forteq… Read more . . .
-
Sorrento Therapeutics has initiated a Phase 2 trial of its CoviDrops intranasal neutralizing antibody in COVID-19 patients in the UK, the company said. The trial is expected to enroll 350 COVID-19 patients who have mild… Read more . . .
-
Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda… Read more . . .
-
Inhalon Biopharma has announced that it is partnered with Celltrion to develop a nebulized formulation of regdanvimab, a monoclonal antibody for the treatment of COVID-19, which will be known as IN-006. In May 2021, Inhalon… Read more . . .
-
OINDP research and development specialist Nanopharm has partnered with Leyden Labs for development of Leyden Labs antiviral nasal spray candidates, the companies have announced. Nanopharm, which was acquired by Aptar Pharma in 2019, will develop… Read more . . .
-
Meissa Vaccines said that a SARS-CoV-2 challenge test of its MV-014-212 intranasal live attenuated vaccine candidate in non-human primates demonstrated similar efficacy for a single dose compared to currently available vaccines, and the intranasal vaccine stimulated… Read more . . .
-
Device developer Iconovo has received an order worth up to 4.9 million Swedish kronor from Immune System Regulation (ISR) for an intranasal version of Iconovo’s ICOone single dose DPI, the company said. In March 2021,… Read more . . .
-
Philip Morris International (PMI) has announced an offer of ~£1.05 billion for the acquisition of inhalation CDMO Vectura. In May 2021, Vectura announced that it would be acquired by the Carlyle Group for £958 million.… Read more . . .
-
AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that “Success against these common viruses could also indicate that an Ampligen… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA